Filing Flows › Canopy Growth (CGC) › Guidance & outlook

Canopy Growth (CGC) guidance and outlook

Canopy Growth (CGC) initiated its guidance on Nov 6, 2026. Canopy Growth's 10-Q filed Nov 6, 2026 makes 18 forward-looking statements, 2 of them new and 1 no longer said since the filing before.

Guidance and outlook

Forward-looking statements, 10-Q filed Nov 6, 2026

• our international activities, including required regulatory approvals and licensing, anticipated costs and timing, and expected impact;
• our ability to execute on our strategy and the anticipated benefits of such strategy;
• the expected growth in the number of customers using our products;
• the expected methods to be used to distribute and sell our products;
• the anticipated future gross margins of our operations;
• We believe it will stand alongside – and eventually rival – the largest consumer packaged goods industries in the world.
• The full potential of cannabis is just beginning to be unlocked – and we intend to lead that future.
• We believe that this will enable us to compete more effectively, and lead, in today’s rapidly evolving market.
• We are and expect to continue to be Canada’s #1 medical cannabis provider by revenue - We are committed to the high-quality production of medical cannabis products and are equally committed to helping medical professionals confidently prescribe and patients to responsibly use our products.
• We intend to fuel the continued demand for our European Union Good Manufacturing Practices (“EU-GMP”) certified medical grade cannabis internationally with supply from within Europe and from our Canadian EU-GMP certified facility in Kincardine, Ontario.
• In addition, we will continue to maximize our existing routes to market to further our execution on our international growth plans, while leveraging our cannabis expertise and well-established medical brands.
• As markets continue to evolve, we believe the role of brands will become more prominent in consumers’ desire for trustworthy products that deliver quality and consistency of experience.

Canopy Growth's latest quarter

Questions

Did Canopy Growth raise or lower its guidance?

Canopy Growth (CGC) initiated its guidance on Nov 6, 2026.

What does Canopy Growth expect?

Management uses Adjusted EBITDA on an internal basis, period-over-period, to evaluate its operating performance, to analyze trends within its business, to assess its performance relative to its competitors, and to establish operational goals and forecasts that are used in allocating resources. The August 2025 ATM Program will be effective until the earlier of (A) June 5, 2027; (B) the issuance and sale of Canopy Shares having an aggregate offering price of US$200 million on the terms and subject to the conditions set forth in the August 2025 Equity Distribution Agreement; (C) the date on which

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.